Arrowhead Pharmaceuticals Inc. News Releases http://ir.arrowheadpharma.com/ Arrowhead Pharmaceuticals Inc. News Releases en Arrowhead Pharmaceuticals to Present at Upcoming June 2019 Conferences http://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-present-upcoming-june-2019-conferences PASADENA, Calif. --(BUSINESS WIRE)--May 31, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Jefferies 2019 Global Health Care Conference – New York , June 4-7, 2019 June 6 , 9:30 a.m. Fri, 31 May 2019 16:00:00 -0400 Arrowhead Pharmaceuticals Inc. News Releases 14631 Arrowhead Pharmaceuticals Reports Fiscal 2019 Second Quarter Results http://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-reports-fiscal-2019-second-quarter — Conference Call and Webcast Today at 4:30 p.m. EDT PASADENA, Calif. --(BUSINESS WIRE)--May 8, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2019 second quarter ended March 31, 2019 . The company is hosting a conference call at 4:30 p.m. Wed, 08 May 2019 16:00:00 -0400 Arrowhead Pharmaceuticals Inc. News Releases 14571 Arrowhead Pharmaceuticals to Present at Upcoming May 2019 Conferences http://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-present-upcoming-may-2019-conferences PASADENA, Calif. --(BUSINESS WIRE)--May 2, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Bank of America Merrill Lynch 2019 Health Care Conference – Las Vegas , May 14-16, 2019 May 15 , 8:40 a.m. Thu, 02 May 2019 07:30:00 -0400 Arrowhead Pharmaceuticals Inc. News Releases 14566 Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Second Quarter Results http://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-webcast-fiscal-2019-second-quarter PASADENA, Calif. --(BUSINESS WIRE)--Apr. 24, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 8, 2019 , at 4:30 p.m. EDT to discuss its financial results for the fiscal 2019 second quarter ended March 31, 2019 . Wed, 24 Apr 2019 16:00:00 -0400 Arrowhead Pharmaceuticals Inc. News Releases 14536 Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million Milestone Payment from Janssen http://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-begins-triple-combination-cohort-chronic-hbv-patients PASADENA, Calif. --(BUSINESS WIRE)--Apr. 24, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has begun dosing in a new triple combination cohort (cohort 12) that includes JNJ-3989 (formerly ARO-HBV) and additional undisclosed agents selected by Janssen Pharmaceuticals, Wed, 24 Apr 2019 07:30:00 -0400 Arrowhead Pharmaceuticals Inc. News Releases 14531 Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease http://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-receives-fda-clearance-begin-phase-23 PASADENA, Calif. --(BUSINESS WIRE)--Apr. 15, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has received clearance from the U.S. Food and Drug Administration to proceed with an adaptive Phase 2/3 trial with the potential to serve as a pivotal registrational study of Mon, 15 Apr 2019 07:30:00 -0400 Arrowhead Pharmaceuticals Inc. News Releases 14516 Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress™ http://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-presents-clinical-data-jnj-3989-aro-hbv-international PASADENA, Calif. --(BUSINESS WIRE)--Apr. 12, 2019-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the presentation of clinical data from an ongoing Phase 1/2 study (AROHBV1001) of JNJ-3989 (formerly ARO-HBV), a third-generation subcutaneously administered RNA interference (RNAi) Fri, 12 Apr 2019 12:45:00 -0400 Arrowhead Pharmaceuticals Inc. News Releases 14511 Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents and Reverses Alpha-1 Liver Disease at The International Liver Congress™ http://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-preclinical-data-demonstrates-rnai-therapy-prevents PASADENA, Calif. --(BUSINESS WIRE)--Apr. 12, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented preclinical data at The International Liver Congress™ 2019 (ILC), the annual meeting of the European Association for the Study of the Liver (EASL), demonstrating that sustained Fri, 12 Apr 2019 06:00:00 -0400 Arrowhead Pharmaceuticals Inc. News Releases 14506 Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) http://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-reports-inducement-grants-under-6 PASADENA, Calif. --(BUSINESS WIRE)--Mar. 29, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on March 22, 2018 , the Compensation Committee of the Board of Directors approved "inducement" grants to 7 new Fri, 29 Mar 2019 16:30:00 -0400 Arrowhead Pharmaceuticals Inc. News Releases 14471 Arrowhead Pharmaceuticals Files IND for Pivotal Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease http://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-files-ind-pivotal-phase-23-study-aro PASADENA, Calif. --(BUSINESS WIRE)--Mar. 18, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration ( FDA ) for an adaptive Phase 2/3 trial with the potential to serve as a Mon, 18 Mar 2019 07:30:00 -0400 Arrowhead Pharmaceuticals Inc. News Releases 14451